Corbus Pharmaceuticals Holdings (CRBP) Common Equity (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Common Equity of $147.5 million for Q4 2025, up 3.56% year-over-year from $142.4 million in Q4 2024, and up 60.07% quarter-over-quarter from $92.1 million in Q3 2025.
Corbus Pharmaceuticals Holdings (CRBP) Common Equity (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Common Equity history runs 13 years deep, the most recent figure standing at $147.5 million for Q4 2025.
- In Q4 2025, Common Equity rose 3.56% year-over-year to $147.5 million; the TTM figure through Dec 2025 stood at $147.5 million (up 3.56% YoY), while the FY2025 annual figure was $147.5 million, up 3.56% from the prior year.
- Common Equity for Q4 2025 stood at $147.5 million, up from $92.1 million in the prior quarter.
- The five-year high for Common Equity was $150.5 million in Q3 2024, with the low at -$6.9 million in Q4 2023.
- The 5-year median for Common Equity is $77.3 million (2021), against an average of $75.7 million.
- The sharpest annual moves came in 2023 and 2024: Common Equity plunged 120.93% in 2023, then soared 48136.54% in 2024.
- Corbus Pharmaceuticals Holdings' Common Equity stood at $69.1 million in 2021, then sank by 52.26% to $33.0 million in 2022, then sank by 120.93% to -$6.9 million in 2023, then soared by 2162.68% to $142.4 million in 2024, then climbed by 3.56% to $147.5 million in 2025.
- Business Quant data shows CRBP's Common Equity at $147.5 million in Q4 2025, $92.1 million in Q3 2025, and $111.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Corbus Pharmaceuticals Holdings | 121.72 Mn | -41.55 Mn | - | 147.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 147.50 Mn |
| Sep 30, 2025 | 92.15 Mn |
| Jun 30, 2025 | 110.99 Mn |
| Mar 31, 2025 | 127.11 Mn |
| Dec 31, 2024 | 142.43 Mn |
| Sep 30, 2024 | 150.50 Mn |
| Jun 30, 2024 | 125.54 Mn |
| Mar 31, 2024 | 96.97 Mn |
| Dec 31, 2023 | -6.91 Mn |
| Sep 30, 2023 | 312,000.00 |
| Jun 30, 2023 | 9.52 Mn |
| Mar 31, 2023 | 16.46 Mn |
| Dec 31, 2022 | 32.99 Mn |
| Sep 30, 2022 | 41.95 Mn |
| Jun 30, 2022 | 49.47 Mn |
| Mar 31, 2022 | 61.16 Mn |
| Dec 31, 2021 | 69.11 Mn |
| Sep 30, 2021 | 77.63 Mn |
| Jun 30, 2021 | 76.96 Mn |
| Mar 31, 2021 | 91.52 Mn |